Pioneering Salivary Diagnostics.
We develop non-invasive saliva-based tools for rapid testing, sample collection, and molecular diagnostics—enabling earlier disease detection and better healthcare outcomes worldwide.
Mission & Focus
Founded in 2002, Oasis Diagnostics® addresses the need for non-invasive saliva-based technology for rapid testing, sample collection, and molecular diagnostics (DNA, RNA, proteins) in Life Sciences.
The Company directs research toward oral-based rapid, point-of-care, laboratory-based, and molecular products that improve healthcare quality for global customers, backed by a portfolio of issued US, EU, and international patents.
At a Glance
-
01Non-invasive salivary diagnostics for early detection
-
02Rapid, point-of-care, and laboratory-ready tools
-
03Issued patents across US, EU, and international markets
-
04Global partnerships in genomics and pharmacogenomics
Our Expertise
Diagnostic Frontiers
Oral Fluid Products
A proprietary range of oral fluid collection and testing products designed for accuracy and ease of use.
VerOFy®, Versi•SAL®, DNA•SAL™, Super•SAL™, RNAPro•SAL™, LIAM™ reader.
Exclusive NA distributor for ViennaLab Diagnostics assays (KRAS, BRAF, Alzheimer's, CVD, and more).
Point of Care
Immediate results where decisions matter most. We focus on rapid diagnosis to support earlier treatment and cost-effective care.
VerOFy® platform supports qualitative and quantitative saliva-based tests using lateral flow immunochromatography, latex agglutination, and magnetic beads for stress, dehydration, drugs of abuse, infectious diseases, steroid hormones, oncology, Alzheimer's, and Parkinson's.
Molecular Diagnostics
Unlocking genetic insights to reveal predispositions and guide highly personalized treatment choices.
RNAPro•SAL™ and DNA•SAL™ tools isolate RNA, proteins, or DNA for downstream PCR, genotyping, microarrays, and sequencing with validated methodologies.
Laboratory Testing
Providing standardized oral fluid collection tools for mainstream laboratory diagnostics globally.
Versi•SAL® (whole saliva), UltraSal-2™ (large volume), and Super•SAL™ (universal collection). Open to licensing, distribution, and partnering worldwide. Protected by issued patents.
Partnering & Collaboration
Oasis Diagnostics® seeks partners with innovative, synergistic technologies that advance salivary diagnostics. Collaboration and distribution opportunities are welcomed within our strategic focus.
Pharmacogenomic Tests
Immunoassays for Coumadin (Warfarin) response, HIV HAART response, and 5-fluorouracil chemotherapy. Partnership with Operon S.A. (Zaragoza, Spain) for genomic strip tests (celiac disease, AZF micro-deletions).
Trademarks & Portfolio
VerOFy®, DNA•SAL™, Versi•SAL®, 4saliva®, Super•SAL™, RNAPro•SAL™, and Oasis Diagnostics® are trademarks covered by US and international patent submissions and issued patents.
Scientific Advisors
Guided by world-class leaders in psychoneuroendocrinology, biomarker development, and translational neuroscience.
Dr. Elizabeth (Birdie) Shirtcliff
Editor in chief of Psychoneuroendocrinology and research professor at University of Oregon. Uses noninvasive biospecimens, including saliva, to study biological and behavioral factors in children and adolescents. Focused on stress-responsive hormones and long-term biological changes; longstanding collaborator with Oasis Diagnostics®.
Professor Chamindie Punyadeera
Innovator and advocate for women in STEMM; leads salivary diagnostics and liquid biopsy laboratory for biomarker development from concept to commercialization. Accelerates precision health through validated biomarkers for risk stratification, prognosis, and treatment response. Griffith University.
Dr. Chi Udeh-Momoh, PhD, FHEA
Translational Neuroscientist based at Wake Forest University School of Medicine with expertise in dementia prediction and prevention. Founding Chair of the Saliva Biomarkers for Dementia Research workgroup (Alzheimer's Association ISTAART). Co-Leads the World-Wide FINGERS Biomarker Consortium and the Global CEOi/Davos Alzheimer's Collaborative.